http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Kyong-Hwa Jun(전경화),Yong-Sung Won(원용성),Gun-Hyung Na(나건형),Young-Jin Suh(서영진),Hyun-Min Cho(조현민),Woo-Bae Park(박우배),Hyung-Min Chin(진형민),Chung-Soo Chun(전정수) 대한외과학회 2007 Annals of Surgical Treatment and Research(ASRT) Vol.73 No.5
Purpose: E-cadherin (ECD) plays a pivotal role in integrating the normal tissue architecture and the suppression of cancer invasion, including stomach cancer. The epidemiology of stomach cancers is noticeably different according to the site of the index tumor, even though the stomach cancers all have similar gross shapes. In this study, the relation between the expression of ECD, along with the clinicopathologic parameters and recurrence or survival, were investigated for patients with gastric adenocarcinoma according to the tumor location. Methods: We examined formalin-fixed, paraffin-embedded archival tissues from 50 surgically resectable gastric adenocarcinomas, which were grouped by the index tumor site as follows: distal (antrum) versus proximal (mid and upper body). To elucidate the correlation between the ECD expression and the site of the stomach cancer with the other clinicopathologic factors, we examined the ECD tissue status via performing immunohistochemistry. To compare the rates of recurrence and survival among subgroups, the patients were followed up for an average of 42 months. Results: Among the 50 tumors examined, 28 (56%) tumors showed various degrees of a ECD expression. The gender, age, size, depth of invasion, lymph node metastasis, stage, lymphatic invasion and vascular invasion were not related with the ECD expression. The Lauren classification was correlated with the ECD expression in the mid and upper body stomach cancer, but not in the antral stomach cancer (P=0.042). The expression of ECD was not related with the survival rate (P=0.223). There was no significant difference in the recurrence rate between the subgroups with and without an abnormal expression of ECD (P=0.588). Conclusion: For the mid and upper body stomach cancer, the expression of E-cadherin correlated with the diffuse type of cancer, according to the Lauren classification, but not with the survival rate.
Solitary Neurofibroma of the Stomach
Kyong-Hwa Jun(전경화),Ji-Han Jung(정지한),Hyung-Min Chin(진형민),Woo-Bae Park(박우배) 대한외과학회 2007 Annals of Surgical Treatment and Research(ASRT) Vol.73 No.3
A neurofibroma of the gastrointestinal tract is frequently associated with type 1 neurofibromatosis. A solitary neurofibroma, which refers to a localized neurofibroma occurring in patients without stigmata of neurofibromatosis, can rarely occur in the stomach. The majority of neurofibromas of the stomach remain small and asymptomatic, and are usually found incidentally. Surgical resection is required for symptomatic relief and for confirmation of the diagnosis. Herein, the case of a 68-year-old woman found to have a solitary neurofibroma in the angle of stomach is reported. The patient underwent a laparoscopy assisted distal gastrectomy, with a gastroduodenostomy. The gross, microscopic and immunohistochemical findings were consistent with the diagnosis of a neurofibroma of the stomach.
Amplification of the UQCRFS1 Gene in Gastric Cancers
Jun, Kyong-Hwa,Kim, Su-Young,Yoon, Jung-Hwan,Song, Jae-Hwi,Park, Won-Sang The Korean Gastric Cancer Association 2012 Journal of gastric cancer Vol.12 No.2
Purpose: The specific aim of this study is to unravel a DNA copy number alterations, and to search for novel genes that are associated with the development of Korean gastric cancer. Materials and Methods: We investigated a DNA copy number changes in 23 gastric adenocarcinomas by array-comparative genomic hybridization and quantitative real-time polymerase chain reaction analyses. Besides, the expression of UQCRFS1, which shows amplification in array-CGH, was examined in 186 gastric cancer tissues by an immunohistochemistry, and in 9 gastric cancer cell lines, as well as 24 gastric cancer tissues by immunoblotting. Results: We found common gains at 48 different loci, and a common loss at 19 different loci. Amplification of UQCRFS1 gene at 19q12 was found in 5 (21.7%) of the 23 gastric cancers in an array-comparative genomic hybridization and DNA copy number were increased in 5 (20.0%) out of the 25 gastric cancer in quantitative real-time polymerase chain reaction. In immunohistochemistry, the overexpression of the protein was detected in 105 (56.5%) out of the 186 gastric cancer tissues. Statistically, there was no significant relationship between the overexpression of UQCRFS1 and clinicopathologic parameters (P>0.05). In parallel, the overexpression of UQCRFS1 protein was confirmed in 6 (66.7%) of the 9 gastric cancer cell lines, and 12 (50.0%) of the 24 gastric cancer tissues by immunoblotting. Conclusions: These results suggest that the overexpression of UQCRFS1 gene may contribute to the development and/or progression of gastric cancer, and further supported that mitochondrial change may serve as a potential cancer biomarker.
( Hong Jun Kim ),( In Keun Choi ),( Se Ryeon Lee ),( Seung Tae Kim ),( Hwa Jung Sung ),( Kyong Hwa Park,),( Sang Cheul Oh ),( Jae Hong Seo ),( Sang Won Shin ),( Yeul Hong Kim ),( Jun Suk Kim ) 대한내과학회 2013 대한내과학회 추계학술대회 Vol.2013 No.1
Introduction: Recent study reported that 38 percent of new patients with soft tissue sarcoma were aged more than 65 years. However, few studies reported clinical outcomes after chemotherapy in elderly patients with recurrent or advanced soft tissue sarcoma. Elderly patients hesitate to receive chemotherapy. But, an equal response to chemotherapy is expected in elderly patients as in young patients. Hence, we aimed to study the clinical results of chemotherapy in elderly patients with recurrent or advanced soft tissue sarcoma. Patients and Methods: 97 patients were admitted for chemotherapy at the Korea University Anam, Guro, and Ansan Hospital s between 2003.3 and 2012.4. Patients were treated with an appropriate chemotherapy regimen. Results: The median age of the patients in the entire group was 52 years. Patients received a median of 4 cycles of chemotherapy. The median overall survival for the entire group was 61 months (95% CI: 29.3-92.7 months). 33 patients were identified as elderly patients aged 60 years or older. In the elderly group, the most common type of soft tissue sarcoma was leiomyosarcoma (21.2%). The median number of chemotherapy cycles was three and median survival was 15 months in the elderly group. In the elderly group, one patient had a complete response. There were four partial responses. 14 patients had progressive disease. In the subgroup analysis, 51 of 64 patients (79.75%) in the non-elderly group were responders, while 19 of 33 patients (57.6%) in elderly group responders were responders (Chi-square test p=0.03). However, there was no statistically significant difference in survival between the elderly and non-elderly groups (p=0.11, log-rank test). Disease burden and response to chemotherapy were predictive of survival in elderly patients with recurrent or advanced soft tissue sarcoma. Conclusions: Taking only an age-based decision for systemic chemotherapy seems not to be reasonable in elderly patients with recurrent or advanced soft tissue sarcoma. A judicious decision needs to be taken for selecting the candidate for chemotherapy in elderly patients with recurrent or advanced soft tissue sarcoma after considering the benefit and toxicity of chemotherapy.